"At the 340 mg dose level there was a statistically significant improvement in overall Parkinson's disease clinical status, including LID, versus placebo as measured by physicians using the CGI-C (p=0.0036)."

At first sight that sounds like good news, but I would like to know:

1. ADS-5102 is measured against the placebo. Would it not make sense to measure it against immediate release amantadine?

2. Success is reported for the 340mg dose. The trial included also 260mg and 420 mg doses. What was the outcome for these?

3. Success was reported for the change in UDysRS. Other measures were used such as diaries and MDS-UPDRS. Do these also show improvements?

4. It seems to me that the obvious measurement that would be understandable to lay people would be before and after values of daily hours with LID together with standard Parkinson's parameters. What are the size of these improvements?

Clearly the results are less exciting if these other measurements do not show similar improvements.

John